Alzheimers Parkinsons ALS

NutritionFacts.org is a science-based nonprofit organization founded by Michael Greger, M.D. FACLM, that provides free updates on the latest in nutrition research via bite-sized videos, blogs, podcasts, and infographics. We are strictly non-commercial, without any sponsors, ads, brand partnerships, or paid subscriptions. More than 2,000 videos on virtually every aspect of healthy eating are available online, and new videos and blogs are uploaded weekly. Our reach is global, with a Spanish-language site, Chinese platforms, and video captions in many languages. NutritionFacts.org is a labor of love—a tribute to Dr. Greger’s grandmother whose own life was saved by improving her diet. Videos-of-the-day are released Monday, Wednesday, Friday, and podcasts are released Thursday. Our videos are always ad-free. If you would like to support our work, visit https://nutritionfacts.org/donate/.

AMG Charitable Foundation, Tackle ALS, the ALS Association, ALS Finding a Cure, the Muscular Dystrophy Association, ALS ONE, the Arthur M Blank Family Foundation, I AM ALS, Tambourine ALS Collaborative, and other community fundraising initiatives and donors. Study drug and partial regimen-related fu …

BACKGROUND Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the ...

A just-published study provides new insight into creatine in the context of Alzheimers. For all the references/articles I cited, article is coming tomorrow!#...

Parkinson's New Zealand provides information, education and support to people living with Parkinson's, care partners and healthcare professionals. Parkinson's is a progressive neurological condition which affects over 12,000 New Zealanders. Although it cannot be cured, treatment is available.

Dr Matthew Phillips is an expert on ketosis and in this presentation he discusses recent studies and the impact ketosis has on Parkinson's. This very inform...

This channel is dedicated to helping Persons with Parkinson's Disease to become Parkinson's Warriors fighting their disease wielding the weapon of knowledge about PD and the impact that it has on daily living. Book 1:1 consultation with a Parkinson's Disease Expert here: https://clarity.fm/pdeducation Explore channel memberships here: YouTube: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join Patreon: https://www.patreon.com/pdeducation If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013

PDF | AMPT (alpha-methyl-para-tyrosine) is an inhibitor of tyrosine hydroxylase, the rate-limiting enzyme in dopamine biosynthesis. In clinical... | Find, read and cite all the research you need on ResearchGate

Because the data say RB-190 should work.

Following reports of low striatal dopamine content in Parkinson’s disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson’s. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson’s disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.

Right Brain Bio is developing a data-driven treatment for Parkinson's - one so revolutionary that it will transform disease understanding and treatment.

Dr. Gilbert discusses the seven new medications that were approved to treat Parkinson’s disease motor symptoms since 2017

Exploring Ivermectin’s Neuromodulatory Role in Enhancing Parkinson’s Treatment

Can Ivermectin play a key role in treating Parkinson's Disease? Two peer-reviewed papers—one by Warnecke et al. (2020) and another by Wa...

Cerebral glucose and insulin metabolism is impaired in Alzheimer's disease (AD). Ketones provide alternative energy. Will medium chain triglyceride (MCT) oil, a nutritional source of ketones, impact cognition in AD? This was a 6‐month randomized, ...

Patients in the PD cohort exhibited distinctive microbiota compositions compared to healthy individuals, with unique differential patterns in gut microbiome abundance at the phylum, family, and genus levels that may be associated wtih PD pathogenesis.

Parkinson's disease (PD) is a neurodegenerative disorder and leading cause of death worldwide, whose pathogenesis has been linked to toxic environmental exposures. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (i) to compile, and group by exposure …

Mitochondrial dysfunction is a hallmark of Parkinson's disease (PD) pathogenesis, contributing to increased oxidative stress and impaired endo-lysosomal-proteasome system efficiency underlying neuronal injury. Genetic studies have identified 19 monogenic mutations-accounting for ~10% of PD cases-tha …

Our study demonstrates that systemic trehalose administration preserved the typical histological architecture of the organs involved in its metabolism, supporting its safety as a potential neuroprotective agent.

The search for therapeutic targets for Parkinson's disease (PD) is hindered by the incomplete understanding of the pathophysiology of the disease. Mitochondrial dysfunction is an area with high potential. The neurobiological signaling connections between the gut microbiome and the central nervous sy …

Parkinson's disease (PD) is one of the most common progressive neurodegenerative diseases. It is characterized neuropathologically by the presence of alpha-synuclein containing Lewy Bodies in the substantia nigra of the brain with loss of dopaminergic neurons in the pars compacta of the substantia n …

Peptides are attracting a growing interest for therapeutic applications in biomedicine. In Parkinson's disease (PD), different human endogenous peptides have been associated with beneficial effects, including protein aggregation inhibition, reduced inflammation, or the protection of dopaminergic neu …

Parkinson's disease (PD) is a neurodegenerative disease affecting dopaminergic neurons in the nigrostriatal and gastrointestinal tracts, causing both motor and non-motor symptoms. This study examined the neuroprotective effects of trehalose. This sugar is confined in the gut due to the absence of tr …

Chlorine dioxide was discovered over 200 years ago. It's use has steadily expanded into many industries and therapeutic applications despite a near global regulatory blockade on clinical research.

Parkinson's disease (PD) is a progressive movement disorder resulting primarily from loss of nigrostriatal dopaminergic neurons. PD is characterized by the accumulation of protein aggregates, and evidence suggests that aberrant protein deposition in ...

Transcranial magnetic stimulation (TMS) is an effective method used to diagnose and treat many neurological disorders. Although repetitive TMS (rTMS) has been used to treat a variety of serious pathological conditions including stroke, depression, ...